Placeholder Banner

BIO Sends Letter to President Biden Discussing Collaboration to Ensure Patient Access to COVID Treatments

March 8, 2021

BIO President and CEO Dr. Michelle McMurry-Heath sent President Biden a letter sharing thoughts on how to best work together with global partners to ensure that patients around the world get access to COVID vaccines, therapeutics, and diagnostics.

Download Full Comments Below
Letter to President Biden
Discover More
On Wednesday, December 29th, BIO submitted comments to the Food and Drug Administration’s recent draft guidance for industry entitled, Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the Federal Food, Drug, and…
On Wednesday, July 14th, BIO submitted comments on FDA’s Guidances: 1) Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency Guidance; 2) Updated Manufacturing, Supply…
On Monday, May 9th, BIO submitted comments in response to the FDA’s recent draft guidance on Clinical Pharmacology Considerations for Antibody-Drug Conjugates. In the comments submitted, BIO acknowledged the challenge FDA faces in creating a…